Author Archive: BIOtechNOW Editor

Immuno Oncology – A 30-year Overnight Success Story

Photo Feb 11, 1 30 16 PM

“It was the Rodney Dangerfield space – couldn’t get no respect” One would never guess those words were used to describe immuno-oncology, a field that has recently bloomed into full-fledged frenzy – with private companies raising unprecedented Series As, impressive data being announced and Science designating the field “Breakthrough of the Year” all in 2013. Yet Dr. Jeffrey Weber, an early member in the “i-onc” research community likened the past several decades of immuno-oncology to Read More >

Events, Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Open Communication Helps Reduce Rare Disease Drug Development Risk

115x76allisonMparks

One of the most important keys to successful relationships – be it in life or rare disease drug development – is open, honest and frequent communication, according to a panel of rare disease experts speaking at the Therapeutic Workshop: “Balancing the Rick-Reward in Rare Disease Drug Development” at the BIO CEO & Investor Conference in New York on Monday. Without engaging the key groups at the right time and the right manner, companies entering this Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , ,

Cancer Insurance Checklist: Guía de Cobertura Médica para Personas con Cáncer

20070112

As the world marks World Cancer Day and the U.S. continues to implement the Affordable Care Act, the Cancer Support Community (CSC) is pleased to announce the launch of a Spanish language version of the successful resource, the Cancer Insurance Checklist. This easy-to-use guide is available to assist people with cancer, a history of cancer or at risk for cancer choose a health insurance plan. The need is great.  Nearly a third (31.1 percent) of Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

FDA Check-Up: Drug Development and Manufacturing Challenges

Paul Hastings

I have over 27 years of experience in the biotechnology and pharmaceutical industry. My current company, OncoMed Pharmaceuticals, is working at the cutting edge of oncology research, focused on antibodies that target a specific set of cells within tumors, known as tumor initiating cells, that drive the growth of the tumor and can differentiate into various cell types within the tumor. Currently, we have five products in clinical development in over 13 completed or ongoing Read More >

Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

The Arrival of Actionable Personalized Medicine

kevin-davies115-76

The pace of implementation of next-generation sequencing (NGS) in a clinical context, which almost rivals the development of the technology over the past decade, is driving the cost of a full genome sequence down to just a few thousand dollars. Diagnostic companies and medical centers are now routinely offering comprehensive genome analysis, as evidenced by the recent report from Baylor College of Medicine in the New England Journal of Medicine on the first 250 patients Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , ,